Apothecary Pharma, a North Carolina compounding pharmacy, has initiated a nationwide voluntary recall of 23 vials of sterile injectable products after their sterility could not be assured, according to a Food and Drug Administration notice.
What Happened
The recall covers 22 vials of compounded tirzepatide injection — a GLP-1 medication containing the same active ingredient as Eli Lilly's Mounjaro and Zepbound — and one vial of NAD+ injection. The affected tirzepatide product is an 18 mg/mL prescription injection in a 4 mL multi-dose vial, with recalled lots AP-202622 through AP-202625 and AP-202627 through AP-202644, and beyond-use dates running from October 7 through November 26, 2026. The recalled NAD+ product is a 200 mg/mL injection in a 6 mL multi-dose vial, lot AP-202647.
The FDA classified the action as a Class II recall on October 8, a category reserved for products that may cause temporary or medically reversible health problems, or where the probability of serious harm is remote. The agency has not identified any reported illnesses or injuries linked to the recall to date.
Who Is Affected
The recall applies to patients who received compounded GLP-1 or NAD+ injections supplied by Apothecary Pharma — not to users of FDA-approved name-brand products. Recipients were notified by letter, and the recall remains ongoing. The FDA stated that while a prior inspection found problems that put patients at risk, it has not established a connection between those findings and the current recall.
Timeline
- December 2025: The FDA issued a warning letter to Apothecary Pharma citing serious deficiencies in the company's sterile drug production practices.
- September 24, 2026: Apothecary Pharma initiated the voluntary recall and began notifying recipients by letter.
- October 8, 2026: The FDA classified the recall as Class II.
- October 2026: National news coverage expanded public awareness of the affected lots.
What This Means for Researchers
The recall lands in a regulatory environment that has already tightened around compounded GLP-1s. The FDA removed tirzepatide and semaglutide from its official drug shortage list in late 2024 and early 2025, ending the shortage-era flexibility that had allowed compounding pharmacies to produce copies of these medications at scale. Enforcement attention has since shifted toward sterility assurance and quality control at compounding facilities.
Key takeaways for researchers:
- A prior warning letter does not automatically trigger a recall, but the combination is a strong signal to track when assessing a compounder's reliability.
- A Class II classification reflects the agency's risk assessment at a moment in time, not the absence of risk — sterility failures in injectables can cause serious infections even when reported harm is zero at publication.
- Lot-level traceability is the single most useful factor in a rapid recall response. Suppliers who provide lot numbers and beyond-use dates on every vial make it possible for users to check their stock in minutes instead of guessing.
How to Verify Your Peptides
Whether you use compounded injectables or research-grade peptides, independent verification remains the strongest protection against the kind of quality failure behind this recall. Review our testing methodology, understand the difference between HPLC and LC-MS analysis, and learn what identity, purity, and fill-weight testing actually confirms about a product.
Safe Alternatives
Anyone holding an affected vial should stop using it and contact the pharmacy or prescriber that supplied it for guidance. Anyone experiencing fever, redness, swelling, or worsening pain after an injection should seek medical advice. For those evaluating sources going forward, our peptide research library and vendor directory profile suppliers with documented testing practices, and FDA-approved GLP-1 products, where available by prescription, remain the most tightly regulated option.
Sources
- Regulatory announcements: FDA recall classification records and warning letter files (October 2026)
- Industry reports on the nationwide recall of compounded tirzepatide lots